

## **INFIBEAM AVENUES LIMITED**

(Formerly known as Infibeam Incorporation Limited)
[CIN: L64203GJ2010PLC061366]

**Registered Office**: 28<sup>th</sup> Floor, GIFT Two Building, Block No. 56, Road-5C, Zone-5, GIFT CITY,

Gandhinagar, Taluka & District - Gandhinagar – 382 355 **Tel:** +91 79 67772204, **Fax:** +91 79 67772205 **Email:** <u>ir@ia.ooo</u>, **Website:** <u>www.ia.ooo</u>

## Details of SARs as on March 31, 2020

Disclosures pursuant to Regulation 14 of the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2020:

A. Relevant disclosures in terms of the 'Guidance note on accounting for employee share-based payments' issued by ICAI or any other relevant accounting standards as prescribed from time to time

Members may please refer to the Audited Financial Statement for the Financial Year 2019-20.

## B. Details related to SARs Scheme

The description including terms and conditions of SARs is summarized as under:

Sr.	Description	Details
No.		
1.	Date of Shareholder's Approval	August 11, 2017
2.	Total Number of Options approved under Infibeam Stock Appreciation Rights Scheme 2017	The maximum aggregate number of Shares that may be acquired from the secondary market by the Trust in a financial year and thereby the SARs that may be Granted in a financial year under the Scheme shall not exceed the limit as specified under Regulation 3(10) of the SEBI (SBEB) Regulations.
3.	Vesting requirements	Vesting period as decided and approved by the board in the letters issuing the options to employees.
4.	SAR price or pricing formula	SAR Price means the total amount utilised by the Trust to purchase the Shares from the secondary market divided by the total number of Shares purchased by the Trust. It is clarified herein that the price of each Share while arriving the SAR Price, shall take into account all the costs relating to the acquisition of Shares, including but not limited to the applicable securities transaction tax, brokerage, other taxes, surcharge, cess and other incidental administrative expenses.

5.	Maximum term of SAR granted	The Options granted to a Grantee shall be
J.	Maximum term of SAR granted	capable of being exercised within a period of not
		exceeding five years from the date of Grant of
		the respective Options or such other period as
		may be determined by the Compensation Committee from time to time.
-	Made defende	
6.	Method of settlement	Cash or Equity
7.	Choice of settlement (with the Company or	Combination
	the employee or combination)	
8.	Source of shares	Secondary Market
9.	Variation in terms of options	None
10.	Method used to account for SAR - Intrinsic	Fair Value
	or fair value.	
11.	Where the company opts for expensing of	Not Applicable
	SAR using the intrinsic value of SAR, the	
	difference between the employee	
	compensation cost so computed and the	
	employee compensation cost that shall	
	have been recognized if it had used the fair	
	value of SAR, shall be disclosed. The impact of this difference on profits and on EPS of	
	the company shall also be disclosed.	
12.	SAR movement during the year (For each SA	R scheme).
12.	State movement during the year (1 or each sta	in seneme).
	Particulars	Details
a.	Number of SARs outstanding at the	22,76,311
	beginning of the year	
b.	Number of SARs granted during the year	0
C.	Number of SARs forfeited / lapsed during	2,45,000
	the year	00 = 6044
d.	Number of SARs vested during the year	22,76,311
e.	Number of SARs exercised / settled during	0
	the year	20.24.244
f.	Number of SARs outstanding at the end of	20,31,311
~	the year	20.21.211
g.	Number of SARs exercisable at the end of	20,31,311
h.	the year  k. Employee- wise details of options granted	to
11.	i. Senior Managerial Personnel	NIL
	i. Semoi Manageriai Personnei	INIL
	ii Any other employee who receives -	-
	ii. Any other employee who receives a grant in any one year of option	<del>-</del>
	amounting to 5% or more of option	
	granted during that year	
	iii. Identified employees who were	_
	granted option, during any one	
	year, equal to or exceeding 1% of	
	the issued capital (excluding	
	outstanding warrants and	
	conversions) of the Company at the	
	time of grant	